HollisterStier Contract Manufacturing has signed a Letter of Intent with Prism Pharmaceuticals to develop a process for compounding and fill/finishing Prism’s PM101, an acute care cardiovascular drug. HollisterStier is producing PM101 registration material for clinical trials and is supporting Prism’s filing of an NDA. PM101 will be filled into vials and syringes. Anthony Bonanzino, Ph.D., president and chief executive officer of HollisterStier, said, “HollisterStier is p...